Residents

Cortexyme, Inc.

Cortexyme, Inc.

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.

Area of focus: 
Neuroscience
Commencement date: 
02/11/2015

Share